| GPC-3298306 | GPC-3298306 | Phase 2 Clinical | National Cancer Center Of Japan | Carcinoma, Hepatocellular; Ovarian Neoplasms | Details |
| BOS-342 | PRS-342; BOS-342; PRS-342/BOS-342 | Phase 2 Clinical | Pieris Pharmaceuticals | Carcinoma, Hepatocellular; Solid tumours | Details |
| BOXR-1030 | BOXR-1030 | Phase 2 Clinical | Unum Therapeutics Inc | Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Liposarcoma, Myxoid; Liver Neoplasms; Lung Neoplasms | Details |
| GPC3 targeting CAR-T cell therapy (Essen Biotech) | | Phase 2 Clinical | Essen Biotech | Carcinoma, Ovarian Epithelial; Ovarian Neoplasms | Details |
| AZD-9793 | AZD9793; AZD-9793 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Hepatocellular; Neoplasm Metastasis; Solid tumours | Details |
| CAR-T Cell Therapy Targeting GPC3(Pla General Hospital) | | Phase 2 Clinical | Pla General Hospital | Carcinoma, Hepatocellular | Details |
| MRG-006 | MRG-006A; MRG-006 | Phase 2 Clinical | Shanghai Miracogen Inc | Carcinoma, Hepatocellular; Liver Neoplasms; Neoplasms; Solid tumours | Details |
| C-CAR031 | C-CAR031; AZD-7003; TC-CAR-031; TC-CAR031; C-CAR-031 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| NY-303 | NY-303 | Phase 2 Clinical | NAYA Biosciences Inc | Carcinoma, Hepatocellular; Solid tumours | Details |
| AZD-5851 | AZD-5851; AZD5851 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Hepatocellular | Details |
| NWRD-06 | NWRD-06; NWRD06 | Phase 2 Clinical | Newish Technology (Beijing) Co Ltd | Carcinoma, Hepatocellular | Details |
| GKL-006 | GKL-006; GKL006 | Phase 2 Clinical | Beijing Gene Key Life Technology Co Ltd | Carcinoma, Hepatocellular; Liver Neoplasms; Pancreatic Neoplasms; Psoriasis | Details |
| CMD-011 | CMD-011 | Phase 2 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Carcinoma, Hepatocellular; Liver Neoplasms | Details |
| CAR-GPC3 T-cell (Drum Tower Hospital) | | Phase 2 Clinical | Nanjing Drum Tower Hospital | Carcinoma, Hepatocellular | Details |
| GPC3 CAR-T therapy (Hrain Biotechnology) | | Phase 2 Clinical | Hrain Biotechnology Co Ltd | Carcinoma, Hepatocellular | Details |
| CM-350 | CM-350 | Phase 2 Clinical | Keymed Biosciences Co Ltd | | Details |
| GPC3-CAR-T cell therapy(Origincell Medical Technology) | Ori-CAR-001; Ori-C101(OriCell) | Phase 2 Clinical | OriCell Therapeutics Co Ltd | Carcinoma, Hepatocellular | Details |
| ECT-204 | ECT-204; JWATM-204; ECT204 | Phase 2 Clinical | Eureka Therapeutics Inc, Jw Therapeutics (Shanghai) Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Liver Neoplasms | Details |
| Codrituzumab | GC-33; RO-5137382; RG-7686; ERY-974; PPMX-T001 | Phase 1 Clinical | Perseus Proteomics Inc | Carcinoma, Hepatocellular; Solid tumours | Details |
| GPC3-T2 CAR-T cell therapy (The Second Affiliated Hospital of Guangzhou Medical University) | | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Carcinoma, Hepatocellular; Carcinoma, Squamous Cell | Details |
| GLYCAR T cell therapy (Baylor College of Medicine) | GLYCAR | Phase 1 Clinical | Baylor College Of Medicine | Carcinoma, Hepatocellular; Endodermal Sinus Tumor; Hepatoblastoma; Liposarcoma; Liver Neoplasms; Rhabdoid Tumor; Rhabdomyosarcoma; Wilms Tumor | Details |
| Anti-GPC3 CAR T-cell therapy (Carbiogene Therapeutics) | CBG166; CBG-166 | Phase 1 Clinical | Carbiogene Therapeutics Co Ltd, Nanjing University | Carcinoma, Hepatocellular | Details |
| GPC3-CAR-T cell therapy | CSG-GPC-3; CAR-GPC3 T-cell; GPC3-CAR/CSG-GPC3; anti-GPC-3 CAR T; KJgpc3-001; CT-011 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Solid tumours | Details |
| Anti-GPC3 chimeric antigen receptor T cell therapy (Hunan Zhaotai Yongren Biotech/Guangdong Zhaotai Invivo Biomedicine) | | Phase 1 Clinical | Guangdong Zhaotai Invivo Biomedicine Co Ltd, Hunan Zhaotai Yongren Biotech Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| anti-GPC3 CAR T-cell therapy (National Institutes of Health Clinical Center) | | Phase 1 Clinical | National Institutes Of Health Clinical Center (Cc) | Carcinoma, Hepatocellular | Details |
| anti-GPC3 CAR T-cell therapy (Nanjing Drum Tower Hospital) | | Phase 1 Clinical | Nanjing Drum Tower Hospital | Carcinoma, Hepatocellular | Details |
| GPC3-T2-CAR-T | GPC3-T2-CAR-T | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Carcinoma, Hepatocellular | Details |
| EU-307 | EU307 | Phase 1 Clinical | Eutilex | Carcinoma, Hepatocellular; Liver Neoplasms | Details |
| Ori-CAR-002 | Ori-CAR-002; GPC3-CAR-Ori2 | Phase 1 Clinical | OriCell Therapeutics Co Ltd | | Details |
| SENTI-301 | SENTI-301; SENTI-301A; SN301A | Phase 1 Clinical | Senti Biosciences Inc | Carcinoma, Hepatocellular; Liver Neoplasms | Details |
| Super CAR-T cell therapy (FineImmune Biotechnology) | | Phase 1 Clinical | Guangzhou Fineimmune Biotechnology | Carcinoma, Hepatocellular | Details |
| TC-G203 | TC-G203; TCG203 | Phase 1 Clinical | Beijing GoBroad Hospital | Carcinoma, Hepatocellular; Solid tumours | Details |
| I-124 Codrituzumab | | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd, Hoffmann-La Roche Inc, Memorial Sloan Kettering Cancer Center | Carcinoma, Hepatocellular | Details |
| 225Ac-RYZ-811 | 225Ac-RYZ-811 | Phase 1 Clinical | PeptiDream Inc | Carcinoma, Hepatocellular | Details |
| OriC-902 | OriC-902; OriC902 | Phase 1 Clinical | OriCell Therapeutics Co Ltd | Carcinoma, Hepatocellular | Details |
| BAY-3547926 | BAY3547926; BAY-3547926 | Phase 1 Clinical | Bayer AG | Carcinoma, Hepatocellular | Details |
| MT-303(Myeloid) | MT-303(Myeloid) | Phase 1 Clinical | Myeloid Therapeutics Inc | Carcinoma, Hepatocellular | Details |
| 68Ga-aGPC3-scFv/Fab | 68Ga-aGPC3-scFv/Fab | Phase 1 Clinical | Wuhan Union Hospital | | Details |
| BGB-B2033 | BGB-B-2033; BGB-B2033 | Phase 1 Clinical | Beigene Guangzhou Biologics Manufacturing Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| BC-2027 | BC2027; BC-2027 | Phase 1 Clinical | Wuxi BioCity | Liver Neoplasms; Solid tumours | Details |
| JMT-106 | JMT106; JMT-106 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Solid tumours | Details |
| AST-201 (Aptamer Sciences) | AST-201(Aptamer Sciences) | Phase 1 Clinical | Aptamer Sciences Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Liver Neoplasms; Neoplasms; Solid tumours | Details |
| GPC3/Mesothelin-CAR-γδT Cells therapy(Second Affiliated Hospital Of Guangzhou Medical University) | | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Liver Neoplasms; Lung Neoplasms; Mesothelioma; Pancreatic Neoplasms; Solid tumours | Details |
| ZW-251 | ZW-251 | Phase 1 Clinical | Zymeworks Inc | Carcinoma, Hepatocellular | Details |
| 68Ga-RYZ-811 | RYZ811(68Ga); 68Ga-Ga-RYZ-GPC3; 68Ga-GPC3; 68Ga-RYZ-811; RYZ-811 | Phase 1 Clinical | PeptiDream Inc, RayzeBio Inc | Carcinoma, Hepatocellular | Details |
| GPC3-targeted CAR-T (Peking University) | | Phase 1 Clinical | Peking University | Carcinoma, Hepatocellular | Details |
| CAR (hYP7)-T cells (National Cancer Institute) | | Phase 1 Clinical | National Cancer Institute | Carcinoma, Hepatocellular | Details |
| QLS-31903 | QLS31903; QLS-31903 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | | Details |
| SAR-444200 | SAR-444200 | Phase 1 Clinical | Sanofi | | Details |
| IM-83 CAR-T cell therapy | IM-83; IM83 | Phase 1 Clinical | Imunopharm Technology Co Ltd | Carcinoma, Hepatocellular; Liver Neoplasms; Neoplasms; Osteosarcoma | Details |
| JWATM-214 | JWATM-214; JWATM214 | Phase 1 Clinical | Suzhou Yaomingjunuo Biotechnology Co Ltd | Carcinoma, Hepatocellular; Liver Neoplasms | Details |
| TH-012(Bangentai Biomedical) | TH-012 | Phase 1 Clinical | Shandong Bangentai Biomedical Tech Group Co Ltd | Pancreatic Neoplasms; Stomach Neoplasms | Details |
| B010-A | B010-A | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Carcinoma, Hepatocellular | Details |
| CT-0180 | CT-0180 | Phase 1 Clinical | CARsgen Therapeutics Holdings Ltd | Carcinoma, Hepatocellular | Details |
| HRAIN-011 | HRAIN-011 | Clinical | Hrain Biotechnology Co Ltd | Carcinoma, Hepatocellular | Details |
| [68Ga]Ga-NOTA-G5 | | Clinical | Renji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine | Digestive System Neoplasms | Details |
| [18F]F-RESCA-G5 | | Clinical | Renji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine | Digestive System Neoplasms | Details |
| Anti-GPC3-IRDye800CW | | Clinical | Chinese Academy Of Sciences | | Details |